Neurotechnology Following Traumatic Brain Injury
Key facts
- Who runs it
- Brain State Technologies, LLC
- Where
- Bethesda and Fort Bragg, United StatesSee the 2 sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 80 people enrolled
- Started
- 28 Aug 2018
- Ended
- 1 Jul 2024
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- HIRREM-SOP or Cereset
- Cereset 2x
- Record updated
- 14 August 2023
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 43 criteriaShow less
Who can take part
- 1 Must have symptoms related to concussion or TBI, not healthy controls Age 18 years or older
- 2 Active duty or retired military service member, or dependent beneficiary
- 3 History of mild TBI, confirmed by administration of the Ohio State University TBI
- Identification Method Interview
- 4 At least three months, and no more than ten years, since their most recent TBI
- 5 Persistent symptoms temporally related, or otherwise attributable to, the TBI, such as
- headache or chronic pain, sensory disturbance including auditory, visual or other sensory
- symptoms, balance difficulties, or dizziness. After obtaining informed consent, sufficient
- severity of symptoms for entry into the study will be confirmed by administration of the
- Neurobehavioral Symptom Inventory (NSI), with a score of 23 or higher required for
- inclusion
- 6 Willingness to be randomly assigned to one of the two treatment groups and to provide
- data for all study measures
- 7 Willingness to abstain from alcohol or recreational drug use throughout the intervention
- period and up to 3 weeks after completion of the final office-based intervention session
- This abstention period is intended to support the stabilization of new brain activity
- patterns that may result from the intervention
- 8 For individuals using any of the following medication classes (either regularly scheduled
- or PRN), a willingness both to discontinue or hold those medications at least five (5) halflives
- prior to the initiation of study procedures, and throughout the period of participation
- in the study, as well as to sign a release enabling contact between study staff and their
- prescribing provider, to ensure that the prescriber deems that holding said medication
- during the study period is permissible and reasonable: benzodiazepines, opioids, antipsychotics,
- mood-stabilizers, anti-convulsants, non-benzodiazepine sleep aids (including
- but not limited zolpidem, eszoplicone, zaleplon, trazadone, and diphenhydramine), other
- prescribed sedative-hypnotics, or medical marijuana or cannabinoid medication
- 9 Willingness to abstain from initiation of PRN/as needed usage of the above listed
- medications throughout the period of study participation. This criterion only applies to
- new PRN prescription or usage. There is no requirement to abstain from a new, regularly scheduled prescription for one of the above medications during the course of the study, if the participant's provider
- deems such usage to be indicated. The potential impact of the initiation of any such
- medications during the study will be assessed by conducting sensitivity analyses after the
- completion of the study
- 10 Willingness to alert study investigators of any changes in their medication usage
- throughout the course of their study participation
Who cannot take part
- 2 A history of moderate or severe TBI
- 3 The diagnosis of a psychotic disorder (including schizophrenia and schizoaffective
- disorder), severe depression (PHQ-9 score > 20), bipolar disorder, or active suicidal or
- 6 Meeting criteria for a current alcohol or substance use disorder
- 1 Unable or unwilling to demonstrate an understanding of the nature and intent of the
- study, and/or to complete informed consent procedures
- homicidal ideation
- 4 Physically unable to come to the study visits, or to sit in a chair for up to two hours
- 5 Inability to hear and repeat a phrase spoken at normal conversational volume
Where in United States
- Uniformed Services UniversityBethesda, United States
- Womack Army Medical CenterFort Bragg, United States
About the trial
What the trial wants to find out
This two-part study seeks to improve symptoms such as pain and sleep problems after concussion, or mild traumatic brain injury (mTBI).
Read full original descriptionShow less
Study I evaluates symptoms of mTBI through a series of 10 office sessions in which musical tones are echoed, or mirrored back in real time, to reflect one's own brain activity. Those who take part in the study will be randomly assigned to receive either tones that are based on their brain activity/brainwaves, or random tones.
Study II evaluates symptoms of mTBI through either 10 office sessions of the same acoustic stimulation linked to brain activity/brainwaves as Study I compared to 5 office sessions of acoustic stimulation plus intermittent very low level electrical stimulation of the scalp linked to brain activity.
The 2 groups in the trial
- HIRREM-SOP or CeresetExisting treatment, for comparison
HIRREM-SOP is a novel, noninvasive, closed-loop, BrainEcho, acoustic stimulation neurotechnology to support relaxation and auto-calibration of neural oscillations, using auditory tones to reflect brain frequencies in near real time. This group will have 10 sessions.
- Cereset 2xExisting treatment, for comparison
Participants randomized to the Cereset 2x group will be seated in a comfortable zero-gravity chair identical to those in the HIRREM-SOP arm. They will listen to a pattern of musical notes linked to their brain activity patterns, but also receive intermittent very low level electrical stimulation of the scalp linked to brain activity. This group will only have 5 sessions,
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Randomized Controlled Trials of Closed-loop Allostatic Neurotechnology to Improve Sensory Function and Pain Management After Traumatic Brain Injury
- Publications
- Acoustic neuromodulation with or without micro-voltage tACS reduces post-concussive symptoms.Brain injury, 2025
- Randomized, controlled clinical trial of acoustic stimulation to reduce postconcussive symptoms.Annals of clinical and translational neurology, 2024
- Record updated
- 14 August 2023